BioWorld

July 15, 2004

Genzyme's 2Q Earnings Mask ILEX Merger; Stock Moves Up

Strong sales and earnings propelled Genzyme Corp.'s second-quarter results past estimates and led the company to forecast continued growth that would offset any dilution related to its merger with ILEX Oncology Inc. (BioWorld Today) Read More

Trubion's Series B Brings In $32M For Preclinical SMIPs

FDA, Lobbyists, Government Meet To Debate Reimportation

Vitra Financing Raises $5.5M To Advance Parallel Screening

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 1, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...